Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy
Identifieur interne : 003C26 ( Istex/Corpus ); précédent : 003C25; suivant : 003C27Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy
Auteurs : William A. Briggs ; Somsak Tanawattanacharoen ; Michael J. Choi ; Paul J. Scheel Jr ; Tibor Nadasdy ; Lorraine RacusenSource :
- American Journal of Kidney Diseases [ 0272-6386 ] ; 1996.
English descriptors
- Teeft :
- Beneficial effect, Biopsy, Case report, Clinical features, Creatinine, Defic syndr, Esrd, First report, Glucocorticoid, Histopathology, Hivan, Human immunodeficiency virus, Human immunodeficiency virus infection, Immunodeficiency, Lymphocyte, Microangiopathic, Microangiopathy, National kidney foundation, Nephropathy, Original magnification, Posttreatment, Prednisone, Prednisone dosage, Pretreatment, Pretreatment biopsy, Renal, Renal biopsies, Renal disease, Renal function, Serum creatinine, Sputum cultures, Steroid, Steroid therapy, Therapeutic intervention, Thrombotic, Thrombotic microangiopathic changes, Thrombotic microangiopathy, Zidovudine.
Abstract
Abstract: A 43-YEAR-OLD MAN with rapidly evolving renal failure from biopsy-proven human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) and superimposed thrombotic microangiopathic changes was treated with prednisone. His serum creatinine decreased from 7.5 to 3.9 mg/dL, and the 24-hour protein excretion decreased from 15.7 to 6.1 g over 6 to 8 weeks. As the prednisone was tapered, however, the creatinine began to increase, and a repeat biopsy was done to assist with therapeutic decisions. The major differences from the pretreatment biopsy were marked reductions in interstitial lymphocytes and macrophages and absence of thrombotic microangiopathic lesions. This is the first report comparing pretreatment and posttreatment renal biopsy specimens and the findings provide some insight into the means by which prednisone exerts its beneficial clinical effects acutely on this disease.
Url:
DOI: 10.1016/S0272-6386(96)90477-1
Links to Exploration step
ISTEX:FB58746840373763FD2EAC74E3D3A6043D913FD2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</title><author><name sortKey="Briggs, William A" sort="Briggs, William A" uniqKey="Briggs W" first="William A." last="Briggs">William A. Briggs</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Tanawattanacharoen, Somsak" sort="Tanawattanacharoen, Somsak" uniqKey="Tanawattanacharoen S" first="Somsak" last="Tanawattanacharoen">Somsak Tanawattanacharoen</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Choi, Michael J" sort="Choi, Michael J" uniqKey="Choi M" first="Michael J." last="Choi">Michael J. Choi</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Scheel Jr, Paul J" sort="Scheel Jr, Paul J" uniqKey="Scheel Jr P" first="Paul J." last="Scheel Jr">Paul J. Scheel Jr</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Nadasdy, Tibor" sort="Nadasdy, Tibor" uniqKey="Nadasdy T" first="Tibor" last="Nadasdy">Tibor Nadasdy</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Racusen, Lorraine" sort="Racusen, Lorraine" uniqKey="Racusen L" first="Lorraine" last="Racusen">Lorraine Racusen</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FB58746840373763FD2EAC74E3D3A6043D913FD2</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1016/S0272-6386(96)90477-1</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-6XMJQZWZ-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">003C26</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003C26</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</title><author><name sortKey="Briggs, William A" sort="Briggs, William A" uniqKey="Briggs W" first="William A." last="Briggs">William A. Briggs</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Tanawattanacharoen, Somsak" sort="Tanawattanacharoen, Somsak" uniqKey="Tanawattanacharoen S" first="Somsak" last="Tanawattanacharoen">Somsak Tanawattanacharoen</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Choi, Michael J" sort="Choi, Michael J" uniqKey="Choi M" first="Michael J." last="Choi">Michael J. Choi</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Scheel Jr, Paul J" sort="Scheel Jr, Paul J" uniqKey="Scheel Jr P" first="Paul J." last="Scheel Jr">Paul J. Scheel Jr</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Nadasdy, Tibor" sort="Nadasdy, Tibor" uniqKey="Nadasdy T" first="Tibor" last="Nadasdy">Tibor Nadasdy</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author><author><name sortKey="Racusen, Lorraine" sort="Racusen, Lorraine" uniqKey="Racusen L" first="Lorraine" last="Racusen">Lorraine Racusen</name><affiliation><mods:affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">American Journal of Kidney Diseases</title><title level="j" type="abbrev">YAJKD</title><idno type="ISSN">0272-6386</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="618">618</biblScope><biblScope unit="page" to="621">621</biblScope></imprint><idno type="ISSN">0272-6386</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0272-6386</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Beneficial effect</term><term>Biopsy</term><term>Case report</term><term>Clinical features</term><term>Creatinine</term><term>Defic syndr</term><term>Esrd</term><term>First report</term><term>Glucocorticoid</term><term>Histopathology</term><term>Hivan</term><term>Human immunodeficiency virus</term><term>Human immunodeficiency virus infection</term><term>Immunodeficiency</term><term>Lymphocyte</term><term>Microangiopathic</term><term>Microangiopathy</term><term>National kidney foundation</term><term>Nephropathy</term><term>Original magnification</term><term>Posttreatment</term><term>Prednisone</term><term>Prednisone dosage</term><term>Pretreatment</term><term>Pretreatment biopsy</term><term>Renal</term><term>Renal biopsies</term><term>Renal disease</term><term>Renal function</term><term>Serum creatinine</term><term>Sputum cultures</term><term>Steroid</term><term>Steroid therapy</term><term>Therapeutic intervention</term><term>Thrombotic</term><term>Thrombotic microangiopathic changes</term><term>Thrombotic microangiopathy</term><term>Zidovudine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: A 43-YEAR-OLD MAN with rapidly evolving renal failure from biopsy-proven human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) and superimposed thrombotic microangiopathic changes was treated with prednisone. His serum creatinine decreased from 7.5 to 3.9 mg/dL, and the 24-hour protein excretion decreased from 15.7 to 6.1 g over 6 to 8 weeks. As the prednisone was tapered, however, the creatinine began to increase, and a repeat biopsy was done to assist with therapeutic decisions. The major differences from the pretreatment biopsy were marked reductions in interstitial lymphocytes and macrophages and absence of thrombotic microangiopathic lesions. This is the first report comparing pretreatment and posttreatment renal biopsy specimens and the findings provide some insight into the means by which prednisone exerts its beneficial clinical effects acutely on this disease.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>immunodeficiency</json:string><json:string>nephropathy</json:string><json:string>hivan</json:string><json:string>thrombotic</json:string><json:string>creatinine</json:string><json:string>serum creatinine</json:string><json:string>pretreatment</json:string><json:string>renal</json:string><json:string>esrd</json:string><json:string>glucocorticoid</json:string><json:string>human immunodeficiency virus</json:string><json:string>microangiopathy</json:string><json:string>thrombotic microangiopathy</json:string><json:string>posttreatment</json:string><json:string>zidovudine</json:string><json:string>pretreatment biopsy</json:string><json:string>microangiopathic</json:string><json:string>histopathology</json:string><json:string>lymphocyte</json:string><json:string>biopsy</json:string><json:string>steroid</json:string><json:string>original magnification</json:string><json:string>prednisone</json:string><json:string>thrombotic microangiopathic changes</json:string><json:string>case report</json:string><json:string>sputum cultures</json:string><json:string>prednisone dosage</json:string><json:string>renal disease</json:string><json:string>national kidney foundation</json:string><json:string>first report</json:string><json:string>therapeutic intervention</json:string><json:string>renal function</json:string><json:string>beneficial effect</json:string><json:string>renal biopsies</json:string><json:string>steroid therapy</json:string><json:string>clinical features</json:string><json:string>defic syndr</json:string><json:string>human immunodeficiency virus infection</json:string></teeft></keywords><author><json:item><name>William A. Briggs MD</name><affiliations><json:string>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</json:string></affiliations></json:item><json:item><name>Somsak Tanawattanacharoen MD</name><affiliations><json:string>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</json:string></affiliations></json:item><json:item><name>Michael J. Choi MD</name><affiliations><json:string>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</json:string></affiliations></json:item><json:item><name>Paul J. Scheel, Jr MD</name><affiliations><json:string>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</json:string></affiliations></json:item><json:item><name>Tibor Nadasdy MD</name><affiliations><json:string>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</json:string></affiliations></json:item><json:item><name>Lorraine Racusen MD</name><affiliations><json:string>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>prednisone</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>HIV-associated nephropathy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>renal failure</value></json:item></subject><arkIstex>ark:/67375/6H6-6XMJQZWZ-K</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Short communication</json:string></originalGenre><abstract>Abstract: A 43-YEAR-OLD MAN with rapidly evolving renal failure from biopsy-proven human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) and superimposed thrombotic microangiopathic changes was treated with prednisone. His serum creatinine decreased from 7.5 to 3.9 mg/dL, and the 24-hour protein excretion decreased from 15.7 to 6.1 g over 6 to 8 weeks. As the prednisone was tapered, however, the creatinine began to increase, and a repeat biopsy was done to assist with therapeutic decisions. The major differences from the pretreatment biopsy were marked reductions in interstitial lymphocytes and macrophages and absence of thrombotic microangiopathic lesions. This is the first report comparing pretreatment and posttreatment renal biopsy specimens and the findings provide some insight into the means by which prednisone exerts its beneficial clinical effects acutely on this disease.</abstract><qualityIndicators><score>5.578</score><pdfWordCount>2054</pdfWordCount><pdfCharCount>14136</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>4</pdfPageCount><pdfPageSize>612 x 806 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>127</abstractWordCount><abstractCharCount>903</abstractCharCount><keywordCount>3</keywordCount></qualityIndicators><title>Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</title><pmid><json:string>8840956</json:string></pmid><pii><json:string>S0272-6386(96)90477-1</json:string></pii><genre><json:string>brief-communication</json:string></genre><host><title>American Journal of Kidney Diseases</title><language><json:string>unknown</json:string></language><publicationDate>1996</publicationDate><issn><json:string>0272-6386</json:string></issn><pii><json:string>S0272-6386(00)X0116-3</json:string></pii><volume>28</volume><issue>4</issue><pages><first>618</first><last>621</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1996</json:string></date><geogName></geogName><orgName><json:string>American Journal</json:string><json:string>Division of Nephrology</json:string><json:string>The Johns Hopkins University</json:string><json:string>National Institute of Allergy and Infectious Diseases</json:string><json:string>National Kidney Foundation, Inc</json:string><json:string>Johns Hopkins Hospital, Baltimore, MD</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Lorraine Racusen</json:string><json:string>Tibor Nadasdy</json:string><json:string>Urinalysis</json:string><json:string>Paul J. Scheel</json:string><json:string>Serologies</json:string><json:string>Michael J. Choi</json:string><json:string>William A. Briggs</json:string><json:string>Somsak Tanawattanacharoen</json:string></persName><placeName><json:string>Baltimore</json:string><json:string>MD</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Smith et al</json:string><json:string>October 1994</json:string><json:string>February 1995</json:string><json:string>December 1994</json:string><json:string>Phinney et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-6XMJQZWZ-K</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - urology & nephrology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - urology & nephrology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Nephrology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - informatique, statistique et modelisations biomedicales</json:string></inist></categories><publicationDate>1996</publicationDate><copyrightDate>1996</copyrightDate><doi><json:string>10.1016/S0272-6386(96)90477-1</json:string></doi><id>FB58746840373763FD2EAC74E3D3A6043D913FD2</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-6XMJQZWZ-K/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-6XMJQZWZ-K/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-6XMJQZWZ-K/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1996</date></publicationStmt><notesStmt><note type="brief-communication" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">Section title: Case report</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</title><author xml:id="author-0000"><persName><forename type="first">William A.</forename><surname>Briggs</surname></persName><roleName type="degree">MD</roleName><note type="biography">Address reprint requests to William A. Briggs, MD, The Johns Hopkins University School of Medicine, Division of Nephrology, Ross Building 958, 720 Rutland Ave, Baltimore, MD 21205.</note><affiliation>Address reprint requests to William A. Briggs, MD, The Johns Hopkins University School of Medicine, Division of Nephrology, Ross Building 958, 720 Rutland Ave, Baltimore, MD 21205.</affiliation><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Somsak</forename><surname>Tanawattanacharoen</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Michael J.</forename><surname>Choi</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Paul J.</forename><surname>Scheel, Jr</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Tibor</forename><surname>Nadasdy</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Lorraine</forename><surname>Racusen</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation></author><idno type="istex">FB58746840373763FD2EAC74E3D3A6043D913FD2</idno><idno type="ark">ark:/67375/6H6-6XMJQZWZ-K</idno><idno type="DOI">10.1016/S0272-6386(96)90477-1</idno><idno type="PII">S0272-6386(96)90477-1</idno></analytic><monogr><title level="j">American Journal of Kidney Diseases</title><title level="j" type="abbrev">YAJKD</title><idno type="pISSN">0272-6386</idno><idno type="PII">S0272-6386(00)X0116-3</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="618">618</biblScope><biblScope unit="page" to="621">621</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1996</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: A 43-YEAR-OLD MAN with rapidly evolving renal failure from biopsy-proven human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) and superimposed thrombotic microangiopathic changes was treated with prednisone. His serum creatinine decreased from 7.5 to 3.9 mg/dL, and the 24-hour protein excretion decreased from 15.7 to 6.1 g over 6 to 8 weeks. As the prednisone was tapered, however, the creatinine began to increase, and a repeat biopsy was done to assist with therapeutic decisions. The major differences from the pretreatment biopsy were marked reductions in interstitial lymphocytes and macrophages and absence of thrombotic microangiopathic lesions. This is the first report comparing pretreatment and posttreatment renal biopsy specimens and the findings provide some insight into the means by which prednisone exerts its beneficial clinical effects acutely on this disease.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>prednisone</term></item><item><term>HIV-associated nephropathy</term></item><item><term>renal failure</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1996">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-6XMJQZWZ-K/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="sco"><item-info><jid>YAJKD</jid><aid>96904771</aid><ce:pii>S0272-6386(96)90477-1</ce:pii><ce:doi>10.1016/S0272-6386(96)90477-1</ce:doi><ce:copyright type="unknown" year="1996"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Case report</ce:textfn></ce:dochead><ce:title>Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</ce:title><ce:author-group><ce:author><ce:given-name>William A.</ce:given-name><ce:surname>Briggs</ce:surname><ce:degrees>MD</ce:degrees><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Somsak</ce:given-name><ce:surname>Tanawattanacharoen</ce:surname><ce:degrees>MD</ce:degrees></ce:author><ce:author><ce:given-name>Michael J.</ce:given-name><ce:surname>Choi</ce:surname><ce:degrees>MD</ce:degrees></ce:author><ce:author><ce:given-name>Paul J.</ce:given-name><ce:surname>Scheel</ce:surname><ce:suffix>Jr</ce:suffix><ce:degrees>MD</ce:degrees></ce:author><ce:author><ce:given-name>Tibor</ce:given-name><ce:surname>Nadasdy</ce:surname><ce:degrees>MD</ce:degrees></ce:author><ce:author><ce:given-name>Lorraine</ce:given-name><ce:surname>Racusen</ce:surname><ce:degrees>MD</ce:degrees></ce:author><ce:affiliation><ce:textfn>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address reprint requests to William A. Briggs, MD, The Johns Hopkins University School of Medicine, Division of Nephrology, Ross Building 958, 720 Rutland Ave, Baltimore, MD 21205.</ce:text></ce:correspondence></ce:author-group><ce:date-received day="19" month="3" year="1996"></ce:date-received><ce:date-accepted day="13" month="6" year="1996"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>A 43-YEAR-OLD MAN with rapidly evolving renal failure from biopsy-proven human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) and superimposed thrombotic microangiopathic changes was treated with prednisone. His serum creatinine decreased from 7.5 to 3.9 mg/dL, and the 24-hour protein excretion decreased from 15.7 to 6.1 g over 6 to 8 weeks. As the prednisone was tapered, however, the creatinine began to increase, and a repeat biopsy was done to assist with therapeutic decisions. The major differences from the pretreatment biopsy were marked reductions in interstitial lymphocytes and macrophages and absence of thrombotic microangiopathic lesions. This is the first report comparing pretreatment and posttreatment renal biopsy specimens and the findings provide some insight into the means by which prednisone exerts its beneficial clinical effects acutely on this disease.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="idt"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>prednisone</ce:text></ce:keyword><ce:keyword><ce:text>HIV-associated nephropathy</ce:text></ce:keyword><ce:keyword><ce:text>renal failure</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy</title></titleInfo><name type="personal"><namePart type="given">William A.</namePart><namePart type="family">Briggs</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation><description>Address reprint requests to William A. Briggs, MD, The Johns Hopkins University School of Medicine, Division of Nephrology, Ross Building 958, 720 Rutland Ave, Baltimore, MD 21205.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Somsak</namePart><namePart type="family">Tanawattanacharoen</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael J.</namePart><namePart type="family">Choi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul J.</namePart><namePart type="family">Scheel, Jr</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tibor</namePart><namePart type="family">Nadasdy</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lorraine</namePart><namePart type="family">Racusen</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Medicine and Pathology, The Johns Hopkins Hospital, Baltimore, MD USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="Short communication" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued><copyrightDate encoding="w3cdtf">1996</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: A 43-YEAR-OLD MAN with rapidly evolving renal failure from biopsy-proven human immunodeficiency virus (HIV)-associated nephropathy (HIVAN) and superimposed thrombotic microangiopathic changes was treated with prednisone. His serum creatinine decreased from 7.5 to 3.9 mg/dL, and the 24-hour protein excretion decreased from 15.7 to 6.1 g over 6 to 8 weeks. As the prednisone was tapered, however, the creatinine began to increase, and a repeat biopsy was done to assist with therapeutic decisions. The major differences from the pretreatment biopsy were marked reductions in interstitial lymphocytes and macrophages and absence of thrombotic microangiopathic lesions. This is the first report comparing pretreatment and posttreatment renal biopsy specimens and the findings provide some insight into the means by which prednisone exerts its beneficial clinical effects acutely on this disease.</abstract><note type="content">Section title: Case report</note><subject><genre>Keywords</genre><topic>prednisone</topic><topic>HIV-associated nephropathy</topic><topic>renal failure</topic></subject><relatedItem type="host"><titleInfo><title>American Journal of Kidney Diseases</title></titleInfo><titleInfo type="abbreviated"><title>YAJKD</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1996</dateIssued></originInfo><identifier type="ISSN">0272-6386</identifier><identifier type="PII">S0272-6386(00)X0116-3</identifier><part><date>1996</date><detail type="volume"><number>28</number><caption>vol.</caption></detail><detail type="issue"><number>4</number><caption>no.</caption></detail><extent unit="issue-pages"><start>475</start><end>630</end></extent><extent unit="pages"><start>618</start><end>621</end></extent></part></relatedItem><identifier type="istex">FB58746840373763FD2EAC74E3D3A6043D913FD2</identifier><identifier type="ark">ark:/67375/6H6-6XMJQZWZ-K</identifier><identifier type="DOI">10.1016/S0272-6386(96)90477-1</identifier><identifier type="PII">S0272-6386(96)90477-1</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-6XMJQZWZ-K/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Lorraine/explor/InforLorV4/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003C26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Lorraine
|area= InforLorV4
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:FB58746840373763FD2EAC74E3D3A6043D913FD2
|texte= Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy
}}
| This area was generated with Dilib version V0.6.33. |  |